Sandbox Reserved 200: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA, Lexi Gehring, R. Jeremy Johnson, Jaime Prilusky

Revision as of 19:08, 31 March 2011 view source Lexi Gehring (talk \| contribs) 102 edits No edit summary ← Older edit		Revision as of 19:10, 31 March 2011 view source Lexi Gehring (talk \| contribs) 102 edits No edit summary Newer edit →
Line 29:		Line 29:


	All oligomers of RNase A have antitumor activity, but the higher ordered oligomers show greater activity. <ref name="tumor"/> Though the higher ordered oligomers are more active, they are also much more unstable when ''in vivo''. The pathway of the oligomer once it is inside the cell is unknown, but they do seem to be unregulated. <ref name="tumor"/> In cancer cells because the movement of proteins into the nucleus is unregulated, oligomers can sometimes enter into the nucleus. Once the oligomer is in the nucleus, it is able to degrade RNA and DNA hybrids.<ref name="tumor"/> This will eventually prevent the cell from dividing and decrease the tumor size.		All oligomers of RNase A have antitumor activity, but the higher ordered oligomers show greater activity. <ref name="tumor"/> Though the higher ordered oligomers are more active, they are also much more unstable when ''in vivo''. The pathway of the oligomer once it is inside the cell is unknown, but they do seem to be unregulated. <ref name="tumor"/> In cancer cells because the movement of proteins into the nucleus is unregulated, oligomers can sometimes enter into the nucleus. Once the oligomer is in the nucleus, it is able to degrade RNA and DNA hybrids.<ref name="tumor"/> This will eventually prevent the cell from dividing and decrease the tumor size. Before using oligomers as an antitumor drug, the pathway of the oligomers into and in the cell needs to be monitored so that the oligomers do not degrade dsRNA in healthy cells.